OptiNose Inc. priced its initial public offering late Thursday at $16 a share, the midpoint of its $15 to $17 range, according to Renaisannce Capital, an IPO investment manager. The company, which has developed a nasal spray treatment for chronic rhinosinusitis, offered 7.5 million shares to raise $120 million, after increasing the offer from an original plan to sell 6.3 million shares. Shares will start trading on the Nasdaq later Friday under the ticker symbol “OPTN.” Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets were lead managers on the deal.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News